OPA Bulletin

  • News for the Week of June 23, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Call for OPA Committee Members
    • New Podcast Episode Released: LGBTQ+ Care in Pharmacy
    • Updated: COVID-19 Resources and Tools
    • Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
    • OPA's First Virtual Annual General Meeting and Open Forum

    • Ask the Practice Support Network
    • Reminder: Nominate a Candidate for the Bowl of Hygeia

    • Complimentary Live Webcast on June 24: The Positives and Negatives of COVID-19 Testing in Pharmacies
    • Online Program Registration Now Open: Providing LGBTQ+ Inclusive Care At Your Pharmacy
    • Pandemic Tips: Pharmacy Technician’s Role in Supporting Patients and Pharmacy During the Pandemic

    • Business Expense Disability Insurance

    • DDD Notice No. 20104 posted June 22, 2020 Prescription Forgery Alert
    • DDD Notice No. 20105 posted June 22, 2020: ODB Formulary Edition No. 43, Summary of Changes June 30, 2020
    • DDD Notice No. 20106 posted June 23, 2020 Prescription Forgery Alert

    • Health Canada Drug Shortages Updates, June 17, 2020
    • Health Canada Drug Shortages Updates, June 18, 2020

    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Important Safety Information on MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis - Sanofi-Aventis Canada Inc.

  • News for the Week of June 16, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Regulatory Amendments for Expansion of Scope Posted for Public Consultation
    • ICYMI: Removal of the Ministry’s 30-days’ Supply Dispensing Limit Recommendation
    • ICYMI: Message From OPA's CEO: Our Commitment to Create a Diversity Task Force
    • Updated: COVID-19 Resources and Tools
    • Extension of Red Cross First-Aid Certification

    • All OPA Awards Except Bowl of Hygeia Moved to 2021
    • Ask the Customer Experience and Administration Team

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Is Protecting Your Family and Business a Priority?
    • ICYMI: Get Your Reduced Driving Refund

    • DDD Notice No. 20102 posted June 12, 2020 Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation

    • Health Canada Drug Shortages Updates, June 15, 2020
    • Health Canada Drug Shortages Updates, June 16, 2020

    • Certain Metformin Diabetes Drugs Recalled Due to the Presence or Possible Presence of NDMA
    • Risk of Poisoning From Hand Sanitizers Sold in Beverage Containers

  • News for the Week of June 9, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Pharmacist’s Role in Managing Opioid Use Disorder During COVID-19
    • External Research Initiatives and Resources

    • Ask the Practice Support Network
    • OPA’s Newest Member Benefit Partner, Relief Buddy
    • Complete OPA's Conference Survey for a Chance to Win a Prize

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Professional Liability Insurance Claims Reporting

    • DDD Notice No. 20100 Posted June 4, 2020 Prescription Forgery Alert

    • Recall of Certain Hand Sanitizers That May Pose Health Risks

  • News for the Week of June 2, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Guidance for the Provision of Pharmacy Services in Long-term Care During the COVID-19 Pandemic
    • Update on Providing MedsChecks During COVID-19
    • ICYMI: OPA AGM and Open Forum Reminder
    • Updated: OPA's COVID-19 Insurance Exceptions Tool
    • Pharmacists' Matters - Episode 4: OPA’s Member Engagement Initiatives During the Pandemic
    • Resources for Seniors and People with Disabilities through the Ontario Community Support Program
    • OPA's Statement Supporting Diversity and Inclusivity

    • Ask the Customer Experience and Administration Team

    • Pandemic Tips: Financial Resources for Pharmacies Part 2

    • OPA Term 10 Life Insurance Convertible Feature
    • OPA Store Renewal 2020-2021

    • DDD Notice No. 20099 posted June 2, 2020 Prescription Forgery Alert

    • Health Canada Advises Canadians to Help Support the Continued Supply of Medications
    • Health Product InfoWatch - May 2020
    • Consumers Advised to Stop Using Akwaton International Multipurpose Wipes
    • Some Units of Triton Hand Sanitizer Containing Technical-Grade Ethanol Sold in Canada Without the Necessary Risk Information

  • News for the Week of May 26, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Universal Influenza Immunization Program (UIIP) Now Open for Applications
    • ICYMI: OPA Submission to OCP on Regulatory Amendments to Enable Minor Ailments Prescribing
    • Updated: COVID-19 Testing Direction and Reference Document for Symptoms
    • Updated: Chief Medical Officer of Health Directive #2
    • OPA Supplementary FAQs Addressing Executive Officer Notice: Funding of Teva UK-labelled PrSalamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
    • Updated TELUS Health Provider Agreement
    • Pharmacists' Matters - Episode 3: Pharmacy and Pandemic Resources

    • Manulife Advantage Account

    • Reminder: Session Three of the Methadone, Buprenorphine and the Community Complimentary Live Webinar Series
    • Pandemic Tips: Financial Resources for Pharmacies

    • Universal Influenza Immunization Program and OPA Store Insurance

    • DDD Notice No. 20097 Posted May 26, 2020 Prescription Forgery Alert
    • DDD Notice No. 20096 Posted May 26, 2020 Prescription Forgery Alert
    • DDD Notice No. 20095 Posted May 22, 2020: 2020/21 Universal Influenza Immunization Program Notice to Pharmacies
    • DDD Notice No. 20094 Posted May 21, 2020 Executive Officer Notice: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
    • DDD Notice No. 20093 Posted May 21, 2020 ODB Formulary Edition No. 43, Summary of Changes – May 29, 2020
    • DDD Notice No. 20092 Posted May 21, 2020 Prescription Forgery Alert

    • Cisatracurium Omega Multi-Dose (Cisatracurium Besylate Injection): Temporary Change of Ferrule (Metal Seal) Colour to Maintain Continued Supply in Canada - Omega Laboratories Limited
    • Importation of US-labelled Rocuronium Bromide Injection distributed by Avir Pharma Inc. Due to Shortage of Canadian-labelled Rocuronium
    • Importation of US-labelled Rocuronium Bromide Injection Due to Shortage of Canadian-labelled Rocuronium - SteriMax Inc.

  • News for the Week of May 19, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Welcomes Government Support in Managing 30-days' Supply Limits
    • OPA Supports Teva Canada in Mitigation of Salbutamol Shortages
    • Updated: COVID-19 Resources and Tool
    • Health Canada Toolkit: COVID-19 and Substance Use
    • Mental Health Support for Frontline Staff
    • NIHB New Listing and Dispensing Update
    • WHO Academy App for Healthcare Providers

    • Ask the Customer Experience and Administration Team
    • Easier Process to Order PPE from RONCO Announced
    • Reminder: Call for Resolutions

    • Methadone, Buprenorphine and the Community Complimentary Live Webinar Series

    • Store Risk Prevention Tips

    • DDD Notice No. 20088 Posted May 13, 2020 Notice: Making Changes to the Trillium Drug Program in Response to COVID-19
    • DDD Notice No. 20087 Posted May 13, 2020 Executive Officer Notice: Regulatory Amendments to Ontario Drug Benefit Program Co-payments

    • Importation of Spanish-Labelled Salbutamol Aldo-Union inhalers due to Shortage of Canadian-Labelled Salbutamol
    • Importation of Fresenius Propoven 2% due to Shortage of Canadian Labelled Propofol Injection 1% Products
    • Important Safety Information - Importation of Teva UK-Labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage

  • News for the Week of May 12, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OCP Consultation on Expanding Scope of Practice: Pharmacist Prescribing for Minor Ailments
    • Updated: COVID-19 Case Definition and Reference Document for Symptoms
    • Managing Stress When Our World Has Come to a Halt: Free Webinar from PharmacyU
    • COVID-19 Drug Evidence Initiative (CDEI)
    • Nursing Week: May 11 - 17, 2020

    • Ask the Practice Support Network
    • New Pricing for Personal Protective Equipment (PPE) From RONCO
    • ICYMI: OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

    • Pandemic Tips: Medication Renewal

    • What to Consider Before Selling or Buying a Pharmacy
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20086 posted May 6, 2020 Prescription Forgery Alert

    • Important Safety Information for Certain Respirator Masks
    • Unauthorized Test Kits Claiming to Diagnose or Detect COVID-19 Put Your Health at Risk
    • Importation of US-Labelled Ketamine Hydrochloride for Injection due to Potential Shortage of Canadian-Labelled Ketamine
    • Protect yourself and your family from poisonings: always read and follow the label directions when using hand sanitizers, disinfectants, household cleaning products and bleaches

  • News for the Week of May 4, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Pharmcovid19 #PharmacistsOnTheFrontline
    • COVID-19 OPA advocacy web page
    • Updated: COVID-19 pharmacy signage
    • Updated: Return to work guidance tool
    • Mental health resources from Canadian Foundation for Pharmacy and Therappx
    • ICYMI: OPA's position on pandemic pay for publicly-paid pharmacy professionals

    • Ask the Customer Experience and Administration Team
    • OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

    • Pandemic Tips: Opioid Agonist Therapy

    • Get Your Reduced Driving Refund
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20085 Posted May 5, 2020 Prescription Forgery Alert
    • DDD Notice No. 20084 Posted May 1, 2020 Executive Officer Notice: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
    • DDD Notice No. 20083 Posted May 1, 2020 Proposed Regulatory Amendments related to the Trillium Drug Program Deductible
    • DDD Notice No. 20081 Posted April 29, 2020 Executive Officer Notice: Brand Reference Price Regulations Amendment

    • Axid (Nizatidine) Drug Recalled Due to Presence of NDMA
    • Clinical Trial Looking at the Potential Use of Convalescent Plasma to Treat COVID-19
    • Health Product InfoWatch - April 2020
    • Importation of US-Labelled QUELICIN (Succinylcholine Chloride Injection) and US-Labelled Rocuronium Bromide Injection Due to Shortage of Canadian-Labelled Products and Importation of US-Labelled • • Pancuronium Bromide Injection and US-Labelled Vecuronium Bromide for Injection Due to Shortage of Neuromuscular Blocker Products

  • News for the Week of April 28, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Updated OPA's A Pharmacist's Guide to Pandemic Preparedness
    • Updated COVID-19 Pharmacy Signage
    • COVID-19 and Substance Use
    • Strategies for Managing Shortages of Salbutamol
    • OPA Communications Supporting COVID-19 Initiatives
    • Express Scripts Canada - Update - Electronic Data Interchange (EDI) Direct Reimbursement Claim Reversals
    • Express Scripts Canada - NIHB Pharmacy Spring Newsletter
    • Diabetes Pharmacists Network Offers Savings on Diabetes Resources

    • Ask the Practice Support Network

    • New Pandemic Tips from OPA Course Instructors

    • Personal Professional Liability Insurance (PLI) and Privacy Breach
    • New Changes to OPA's Auto and Home Insurance Program
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20080 posted April 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20079 Posted April 28, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies
    • DDD Notice No. 20078 Posted April 27, 2020. Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies
    • DDD Notice No. 20076 Posted April 22, 2020 ODB Formulary – Edition No. 43, Summary of Changes – April 30, 2020

    • Discontinuation of Sale and Distribution of Coumadin® (Warfarin Sodium) Tablets, for Oral Use

    • Chloroquine and Hydroxychloroquine Can Have Serious Side Effects. These Drugs Should Be Used Only Under the Supervision of a Physician

  • News for the Week of April 21, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Guidance Document on Providing Virtual Care in Pharmacy
    • Updated Pharmacy Tools
    • Third-party Payor Tool on Standard Refill Policies
    • COVID-19 Policy Exceptions
    • Pharmacy Staff Return to Work Guidance
    • Post-Consumer Returns of Controlled Substances and the Patch-for-Patch Fentanyl Return Program
    • COVID-19 Guidance for Naloxone Kit Distribution
    • Pharmacists' Matters - Episode 2: Pharmacy in the Face of Pandemic
    • OPA News Headlines

    • Ask the Customer Experience and Administration Team
    • Dell Canada Special Offer

    • New Pandemic Tips from OPA Course Instructors

    • Did You Know Hospital Coverage is Provided by Your OPA Secure Health Plan?
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20075 posted April 21, 2020 Prescription Forgery Alert
    • DDD Notice No. 20074 Posted April 17, 2020 Prescription Forgery Alert
    • DDD Notice No. 20073 Posted April 16, 2020 Prescription Forgery Alert
    • DDD Notice No. 20072 Posted April 15, 2020 Executive Officer Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes During the COVID-19 Public Health Emergency

    • Shortage of Salbutamol Inhalers in Canada
    • Clinical Management Support: Known Interference Between Hemlibra® (Emicizumab Injection) and Lab Assays Used to Diagnose Coagulopathy / DIC Caused by COVID-19 Infection - Hoffmann-La Roche Ltd.
    • Health Canada is Temporarily Authorizing the Use of Technical-Grade Ethanol in Hand Sanitizer Products: Always Follow the Label Directions When Using Alcohol-Based Hand Sanitizers

Back to top